Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Non-Current Deffered Revenue (2020 - 2021)

GeneDx Holdings (WGS) has disclosed Non-Current Deffered Revenue for 2 consecutive years, with $295.0 million as the latest value for Q2 2021.

  • On a quarterly basis, Non-Current Deffered Revenue changed N/A to $295.0 million in Q2 2021 year-over-year; TTM through Jun 2021 was $295.0 million, a N/A change, with the full-year FY2020 number at $132.0 million, changed N/A from a year prior.
  • Non-Current Deffered Revenue was $295.0 million for Q2 2021 at GeneDx Holdings, down from $297.0 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $297.0 million in Q1 2021 to a low of $15.5 million in Q3 2020.